Janssen's Zytiga fails to impress NICE
This article was originally published in Scrip
Executive Summary
Janssen Cilag has failed to convince NICE, the health technology appraisal institute for England and Wales, that its oral prostate cancer drug Zytiga (abiraterone), provides enough benefit to justify the cost. Today's draft recommendations come despite the offer of a patient access scheme and NICE's acknowledgement that the drug does prolong life.